Related Experiment Video

Updated: Dec 11, 2025

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.6K

[Transforming growth factor-β-activated kinase 1 and pathological myocardial hypertrophy]

Ying Li1, Yue Chen1, Dong-Mei Zhang2

  • 1Department of Physiology, Dalian Medical University, Dalian 116044, China.

Sheng Li Xue Bao : [Acta Physiologica Sinica]
|August 22, 2020
PubMed

Insights

Transforming growth factor-β-activated kinase 1 (TAK1) is crucial in pathological cardiac hypertrophy. Targeting TAK1 offers potential for treating clinical myocardial hypertrophy.

Area of Science:

  • Cardiovascular Biology
  • Molecular Signaling Pathways

Background:

  • Cardiac hypertrophy involves physiological and pathological forms of myocardial enlargement.
  • Transforming growth factor-β-activated kinase 1 (TAK1), a MAPKKK family member, is vital in myocardial development and pathological hypertrophy.
  • Pathological cardiac hypertrophy is induced by factors like Angiotensin II or pressure overload via diverse molecular mechanisms.

Purpose of the Study:

  • To review the role of TAK1 in the development of pathological cardiac hypertrophy.
  • To discuss the therapeutic potential of targeting TAK1 for clinical myocardial hypertrophy.

Main Methods:

  • Literature review focusing on TAK1's involvement in cardiac hypertrophy.
  • Analysis of molecular pathways regulating TAK1 activity (e.g., HIF-1α, TGF-β1).

Main Results:

  • TAK1 is implicated in both normal myocardium development and pathological cardiac hypertrophy.
  • Multiple signaling pathways, including hypoxia-inducible factor-1α (HIF-1α) and transforming growth factor-β1 (TGF-β1), modulate TAK1 activity in hypertrophy.
  • TAK1 activation occurs through transcriptional, phosphorylation, or ubiquitination mechanisms.

Conclusions:

  • TAK1 plays a significant role in the pathogenesis of pathological cardiac hypertrophy.
  • TAK1 represents a promising therapeutic target for preventing and treating clinical myocardial hypertrophy.

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.0K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.0K

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
9.9K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
242
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
549